Patents Assigned to Boehringer Ingelheim
  • Perfusion medium for culturing mammalian cells and reducing cell bleed in a perfusion cell culture
    Patent number: 11702628
    Abstract: The invention relates to a method of culturing mammalian cells expressing a heterologous protein in a perfusion cell culture comprising increasing the potassium concentration and decreasing the molar ratio of sodium to potassium to reduce wasteful cell bleed and to increase protein production. The invention further relates to a serum-free perfusion medium comprising a high potassium ion concentration and a low molar ratio of sodium to potassium and to the use of this medium for use in culturing cells in a perfusion culture during production phase or for reducing the cell bleed volume during production phase.
    Type: Grant
    Filed: March 27, 2018
    Date of Patent: July 18, 2023
    Assignee: Boehringer Ingelheim International GmbH
    Inventors: Samantha Wang, Henry Lin
  • H52 IBV vaccine with heterologous spike protein
    Patent number: 11696947
    Abstract: The present invention relates i.a. to an H52 IBV (infectious bronchitis virus) encoding for a heterologous S (spike) protein or fragment thereof. Further, the present invention relates to an immunogenic composition comprising said H52 IBV encoding for a heterologous S (spike) protein or fragment thereof. Furthermore, the present invention relates to methods for immunizing a subject comprising administering to such subject the immunogenic composition of the present invention. Moreover, the present invention relates to methods of treating or preventing clinical signs caused by IBV in a subject of need, the method comprising administering to the subject a therapeutically effective amount of an immunogenic composition according to the present invention.
    Type: Grant
    Filed: October 28, 2019
    Date of Patent: July 11, 2023
    Assignee: Boehringer Ingelheim Vetmedica GmbH
    Inventors: Annika Kraemer-Kuehl, Egbert Siegfried Mundt, Hans-Christian Philipp
  • Alkoxy pyrazoles as soluble guanylate cyclase activators
    Patent number: 11690848
    Abstract: The present invention relates to compounds of formula (I) and pharmaceutically acceptable salts thereof, wherein R1, R2, R3, R4, R5, R6 and R7 are as defined herein, for use in the treatment of diseases or disorders that can be alleviated by sGC activation or potentiation, selected from chronic liver diseases, Non-Alcoholic Steatohepatitis (NASH), cirrhosis and portal hypertension.
    Type: Grant
    Filed: July 9, 2019
    Date of Patent: July 4, 2023
    Assignee: Boehringer Ingelheim International GmbH
    Inventors: Judith Ertle, Jochen Huber, Ruediger Streicher
  • 2-[thiophen-2-yl)formamido]-N-(phenyl)-2-methylpropanamide derivatives and the use thereof as medicament
    Patent number: 11691960
    Abstract: The present invention relates to novel 2-[thiophen-2-yl)formamido]-N-(phenyl)-2-methylpropanamides of formula A and pharmaceutically acceptable salts thereof, wherein R1 to R3 are as defined herein. The invention also relates to processes for the preparation of these compound, pharmaceutical compositions containing them and their use in therapy, particularly in the treatment or prevention of conditions in which inhibition of the indoleamine 2,3-dioxygenase 1 (IDO1) enzyme may be beneficial.
    Type: Grant
    Filed: November 4, 2021
    Date of Patent: July 4, 2023
    Assignee: Boehringer Ingelheim International GmbH
    Inventors: Stephan Georg Mueller, Kelly Allers, Klaus Klinder, Ursula Mueller-Vieira, Henning Priepke, Alexander Pautsch
  • Cyclic ether derivatives of pyrazolo[1,5-A]pyrimidine-3-carboxyamide
    Patent number: 11691977
    Abstract: The invention relates to Spirocyclic ether derivatives of pyrazolo[1,5-a]pyrimidine-3-carboxyamide of general formula (I) which are inhibitors of phosphodiesterase 2, useful in treating central nervous system diseases and other diseases. In addition, the invention relates to processes for preparing pharmaceutical compositions as well as processes for manufacture the compounds according to the invention.
    Type: Grant
    Filed: October 20, 2020
    Date of Patent: July 4, 2023
    Assignee: Boehringer Ingelheim International GmbH
    Inventors: Christoph Hoenke, Barbara Bertani, Marco Ferrara, Giacomo Fossati, Sara Frattini, Riccardo Giovannini, Scott Hobson
  • Compound targeting IL-23A and TNF-alpha and uses thereof
    Patent number: 11680096
    Abstract: The disclosure relates to compounds specific for IL23A and TNF-alpha, compositions comprising the compounds, and methods of use thereof. Nucleic acids, cells, and methods of production related to the compounds and compositions are also disclosed.
    Type: Grant
    Filed: August 26, 2020
    Date of Patent: June 20, 2023
    Assignees: BOEHRINGER INGELHEIM INTERNATIONAL GMBH, MACROGENICS, INC.
    Inventors: Rachel Rebecca Barrett, Leslie S. Johnson, Sanjaya Singh, Kathleen Last-Barney, Daw-Tsun Shih, Patricia Giblin, Scott Brodeur, Nelamangala Nagaraja
  • Inhaler
    Patent number: 11679212
    Abstract: An inhaler, preferably for insertion into a nostril, in particular a horse's nostril, with a pressure generator, which has a tensioning device for the drive, and with a tensioning mechanism for tensioning the tensioning device, whereby the tensioning mechanism has a lever gear for tensioning the tensioning device.
    Type: Grant
    Filed: August 13, 2018
    Date of Patent: June 20, 2023
    Assignee: BOEHRINGER INGELHEIM VETMEDICA GMBH
    Inventors: Marcus Knell, Michael Aven, Benjamin Franzmann, Steffen Schuy, Herbert Wachtel, Guido Endert, Alexander Christ, Horst Wergen
  • VSV Rescue
    Publication number: 20230183650
    Abstract: The present invention relates to a method for rescue of Vesicular Stomatitis Virus (VSV) from DNA in a HEK293 cell line or a HEK293 cell line adapted to suspension growth comprising (a) providing cells from a HEK293 cell line or a HEK293 cell line adapted to suspension growth in cell culture, (b) transfecting the cells with at least one plasmid, wherein the at least one plasmid comprises (i) an expression cassette comprising a VSV genomic cDNA; (ii) at least one expression cassette encoding VSV nucleoprotein (N) protein, VSV phosphoprotein (P) protein, and VSV large (L) protein; and (iii) an expression cassette encoding SV40 Large T antigen; (c) culturing the transfected cells; and (d) harvesting the cell culture supernatant comprising the rescued VSV.
    Type: Application
    Filed: July 8, 2022
    Publication date: June 15, 2023
    Applicant: Boehringer Ingelheim International GmbH
    Inventor: Tobias Nolden
  • RECOMBINANT HVT VECTORS EXPRESSING MULTIPLE ANTIGENS OF AVIAN PATHOGENS AND USES THEREOF
    Publication number: 20230175017
    Abstract: The invention relates to a bonding and forming device for an inner box of a paper box and surface paper.
    Type: Application
    Filed: July 15, 2022
    Publication date: June 8, 2023
    Applicant: BOEHRINGER INGELHEIM ANIMAL HEALTH USA INC.
    Inventors: Michel Bublot, Teshome Mebatsion, Joyce Pritchard, Perry Linz, Aemro Kassa
  • Pharmaceutical composition, methods for treating and uses thereof
    Patent number: 11666590
    Abstract: The present invention relates to certain SGLT-2 inhibitors for treating, preventing, protecting against and/or delaying the progression of chronic kidney disease in patients, for example patients with prediabetes, type 1 or type 2 diabetes mellitus.
    Type: Grant
    Filed: November 10, 2020
    Date of Patent: June 6, 2023
    Assignee: Boehringer Ingelheim International GmbH
    Inventors: Uli Christian Broedl, Odd-Erik Johansen, Eric Williams Mayoux, Nima Soleymanlou, Maximilian von Eynatten, Hans-Juergen Woerle, David Z.I. Cherney, Bruce A. Perkins
  • Tetrazole derivatives as TRPA1 inhibitors
    Patent number: 11661430
    Abstract: The present disclosure provides certain tetrazole derivatives that are inhibitors of transient receptor potential ankyrin 1 (TRPA1), and are therefore useful for the treatment of diseases treatable by inhibition of TRPA1. Also provided are pharmaceutical compositions containing the same, and processes for preparing the same.
    Type: Grant
    Filed: October 13, 2021
    Date of Patent: May 30, 2023
    Assignee: Boehringer Ingelheim International GmbH
    Inventors: Florian Paul Christian Binder, Thomas Martin Fleck, Jens Willwacher
  • Tetrazole derivatives as TRPA1 inhibitors
    Patent number: 11661427
    Abstract: The present disclosure provides certain tetrazole derivatives that are inhibitors of transient receptor potential ankyrin 1 (TRPA1), and are therefore useful for the treatment of diseases treatable by inhibition of TRPA1. Also provided are pharmaceutical compositions containing the same, and processes for preparing the same.
    Type: Grant
    Filed: October 13, 2021
    Date of Patent: May 30, 2023
    Assignee: Boehringer Ingelheim International GmbH
    Inventors: Martin Thomas Fleck, Florian Paul Christian Binder, Jens Willwacher
  • Anti-NRP1A antibodies and their uses for treating eye or ocular diseases
    Patent number: 11661458
    Abstract: Disclosed are antibodies and fragments thereof that target the A-domain of Neuropilin-1 (Nrp1A). Also disclosed are methods of using the anti-Nrp1A antibodies for the treatment of various diseases or disorders.
    Type: Grant
    Filed: September 24, 2020
    Date of Patent: May 30, 2023
    Assignee: Boehringer Ingelheim International GmbH
    Inventors: Nina Zippel, Pankaj Gupta, Fei Han, Sarah Low, Juergen Prestle, Leo Thomas
  • Connecting and container system
    Patent number: 11649104
    Abstract: A connecting system for providing a fluidic connection, preferably between containers, wherein the connecting system has at least two connecting arrangements configured to provide the fluidic connection, namely a first connecting arrangement and a second connecting arrangement, each of which is fluidically sealed in an initial state, wherein the first connecting arrangement has, in particular, an opening region that is deformable outside the opening region and is configured such that deformation causes the first connecting arrangement to open in the opening region.
    Type: Grant
    Filed: May 5, 2021
    Date of Patent: May 16, 2023
    Assignee: BOEHRINGER INGELHEIM VETMEDICA GMBH
    Inventors: Marcus Rainer Rahmel, Guido Endert, Jonas Ruf, Horst Wergen
  • Nebulizer
    Patent number: 11642476
    Abstract: A nebulizer for a fluid, includes a container containing the fluid; a housing part which can be detached from the nebulizer for replacing the container; an inner part; a retaining element connected with and not detachable from the inner part, where the housing part is releasable fixed to the inner part by the retaining element; a delivery mechanism for dispensing the fluid; a manually depressible actuator member, which is a separate part from the retaining element and acts on the retaining element, and wherein the actuator member is depressed to elastically deform or flex the retaining element to allow detachment of the housing part.
    Type: Grant
    Filed: December 15, 2020
    Date of Patent: May 9, 2023
    Assignee: Boehringer Ingelheim International GmbH
    Inventors: Jens Besseler, Frank Herrmann, Holger Holakovsky, Herbert Argauer, Josef Gatz, Andreas Gorshoefer
  • 3-PHENOXYAZETIDIN-1-YL-HETEROARYL PYRROLIDINE DERIVATIVES AND THE USE THEREOF AS MEDICAMENT
    Publication number: 20230131465
    Abstract: The invention relates to 3-phenoxyazetidin-1-yl-heteroaryl pyrrolidine derivatives of general formula (I) which are agonists of GPR52, useful in treating central nervous system diseases and other diseases. In addition, the invention relates to the 3-phenoxyazetidin-1-yl-heteroaryl pyrrolidine derivatives of general formula (I) for use as a medicament, pharmaceutical compositions comprising at least a compound of general formula (I) and processes for preparing pharmaceutical compositions as well as processes for manufacture the compounds according to the invention.
    Type: Application
    Filed: September 9, 2022
    Publication date: April 27, 2023
    Applicants: Boehringer Ingelheim International GmbH, Arena Pharmaceuticals, Inc.
    Inventors: Kai Gerlach, Daniela Gavina Berta, Marco Ferrara, Kirsten Gutsche, Ursula Mueller-Vieira, Scott Hobson, Frank Runge, Graeme Semple, Viktor Vintonyak, Yifeng Xiong
  • Integration Sites in CHO Cells
    Publication number: 20230131164
    Abstract: The present invention relates to the identification of a genomic integration site for heterologous polynucleotides in Chinese Hamster Ovary (CHO) cells resulting in high RNA and/or protein production. More specifically it relates to CHO cells comprising at least one heterologous polynucleotide stably integrated into the S100A gene cluster of the CHO genome and to methods for the production of said CHO cells. Further, the invention relates to a method for the production of a protein of interest using said CHO cell and to the use of said CHO cell for producing a protein of interest at high yield. Integration within these specific target regions leads to reliable, stable and high yielding production of an RNA and/or protein of interest, encoded by the heterologous polynucleotide.
    Type: Application
    Filed: December 6, 2022
    Publication date: April 27, 2023
    Applicant: Boehringer Ingelheim International GmbH
    Inventors: Markus Mueller, Jochen Schaub, Christian Bernloehr, Jennifer Koenitzer
  • INJECTION DEVICE AND A REUSABLE PART THEREFOR
    Publication number: 20230131522
    Abstract: An injection device, in particular an auto-injector, with a single-use part for dispensing an injection solution has a sensor for acquiring a signal, with which an indicator can be determined, which represents a state or a change in state in a process for dispensing the injection solution with the single-use part. Additionally, the injection device has a reusable part, which is held in a detachable manner by coupling to the single-use part and is coupled via a signal connection, wherein the single-use part has the sensor, and/or wherein the reusable part has a reporting system for detecting the single-use part.
    Type: Application
    Filed: February 25, 2021
    Publication date: April 27, 2023
    Applicant: Boehringer Ingelheim International GmbH
    Inventors: Olaf LEBAU, Joerg HEISIEP, Andree JUNG
  • Method and composition for inducing chondrogenesis or tenogenesis in mesenchymal stem cells
    Patent number: 11634689
    Abstract: A cell medium for in vitro inducing chondrogenesis or tenogenesis in mesenchymal stem cells (MSCs). The medium is a glucose medium supplemented with at least one growth factor is chosen from the group of fibroblast growth factors (FGF) or the group of transforming growth factors (TGF), and the FGF or TGF is present in a total concentration of between 1 and 15 ng/ml. In both cases, IGF can be added to enhance the induction process. The use of the cell medium, a method for inducing isolated mesenchymal stem cells (MSCs) and a cell composition obtained by the method are also provided.
    Type: Grant
    Filed: November 20, 2019
    Date of Patent: April 25, 2023
    Assignee: BOEHRINGER INGELHEIM VETERINARY MEDICINE BELGIUM
    Inventors: Sarah Yolande Kristel Broeckx, Jan Hilda Marie Jozef Spaas
  • CONNECTING ARRANGEMENT, CONNECTING SYSTEM, CONTAINER AND CONTAINER SYSTEM
    Publication number: 20230113868
    Abstract: A fluidic connection for producing a connection between a first container and a second container, wherein, for producing a fluidic connection, a first and second connecting arrangement can be coupled to one another and an opening brought about by the coupling, as a result of which a passage is produced which is suitable for interconnecting the interiors of the containers.
    Type: Application
    Filed: January 21, 2021
    Publication date: April 13, 2023
    Applicant: BOEHRINGER INGELHEIM VETMEDICA GMBH
    Inventors: Marcus Rainer RAHMEL, Peter BAUER, Mark BENNETT, Olaf ECKHARDT, Guido ENDERT, Johannes KRIEGER, Philipp ZIEGLER